title: Edwards SAPIEN XT in Native Stenotic Mitral Valve, Open Technique on Cardiopulmonary Bypass: An Option, But Safe?
abstract: A 73-year-old woman underwent open mitral valve replacement with the transcatheter Edwards SAPIEN XT valve (Edwards Lifesciences, Corp, Irvine, CA USA) on cardiopulmonary bypass in a native, stenotic mitral valve. Because of left ventricular outflow tract obstruction, the patient died 25 days after implantation. There are previous reports of transcatheter valve implantation in native mitral valve with procedural success. However, in one case report, the patient died 10 days postoperatively.
authors.affiliation: From the Department of Thoracic and Cardiovascular Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
authors.forename: Gry
authors.initials: G
authors.lastname: Dahle
authors.forename: Kjell Arne
authors.initials: KA
authors.lastname: Rein
authors.forename: Arnt E
authors.initials: AE
authors.lastname: Fiane
mesh_terms: D000368:Aged; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000295:instrumentation*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008946:Mitral Valve Stenosis / Q000601:surgery*; D011474:Prosthesis Design; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects / Q000379:methods*